ReviewJournal of cosmetic dermatology2025
Ocular Surveillance During Off-Label Oral Isotretinoin for Photoaging: A Review of Risks and Monitoring Recommendations.
Review in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular Surveillance During Off-Label Oral Isotretinoin for Photoaging: A Review of Risks and Monitoring Recommendations.Journal of cosmetic dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-dose oral isotretinoin is increasingly used off-label for photoaging, with evidence of clinical and histologic skin improvement.
objectiveTo review ocular risks associated with isotretinoin in aesthetic use and propose monitoring recommendations.
methodsA narrative review of clinical studies, observational data, and mechanistic reports addressing isotretinoin-induced ocular effects was performed, integrating dermatologic and ophthalmologic perspectives.
resultsReported adverse effects include dry eye disease, meibomian gland dysfunction, and, rarely, retinal alterations. Risk may be cumulative in long-term or repeated cosmetic regimens.
conclusionA risk-adapted monitoring approach, emphasizing patient selection, informed consent, and interdisciplinary care, is recommended to balance cosmetic benefits with ocular safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.